DMB (6,7-dichloro-2-methylsulfonyl-3-Ntert-butylaminoquinoxaline) is a quinoxaline-based compound that has been investigated as a glucagon-like peptide-1 receptor (GLP-1R) agonist. To clarify anti-osteoporosis effect of DMB, an osteoporotic mice model was established by ovariectomy (OVX) operation. The OVX mice were given intraperitoneally DMB, exendin-4 (EX-4), or 17β-estradiol (E2) for two months. Then bone mass and structure, and bone morphometric parameters were examined by micro-CT. Weight gain and food consumption, bone turnover markers, and biomechanical strength of the femur were tested, and bone histomorphometry was analyzed. The food intake and weight gain was obviously reduced by E2 or EX-4, but not DMB. However, DMB or EX-4 treatment obviously inhibited skeletal deterioration and enhanced bone strength. The improvement involved in the increased osteoblast number and level of bone formation markers, and reduced osteoclasts number and level of bone resorption markers. In addition, DMB was found to stimulate osteoblastogenesis-related marker gene expression. These results demonstrated that DMB ameliorated bone loss mainly via induction of bone formation, which suggests that the small molecule compound might be applied to the management of postmenopausal osteoporosis.
ByunDWMoonSHKimTLeeHHParkHMKangMIHaYCChungHYYoonBKKimTYChaeSUShinCSYangKHLeeJHChangJSKimSHKimIJKohJMJungJHYiKWYooJJChungDJLeeYKYoonHKHongSKimDYBaekKHKimHJKimYJKangSMinYK.Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea. J Bone Miner Metab2019;
37:563–72
2.
ParizadNBaghiVKarimiEBGhanei GheshlaghR.The prevalence of osteoporosis among iranian postmenopausal women with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Syndr2019;
13:2607–12
3.
AsprayTJHillTR.Osteoporosis and the ageing skeleton. Subcell Biochem2019;
91:453–76
4.
NguyenHTvon SchoultzBNguyenTVThangTXChauTTDucPTHirschbergAL.Sex hormone levels as determinants of bone mineral density and osteoporosis in vietnamese women and men. J Bone Miner Metab2015;
33:658–65
ZhangMXieYZhouYChenXXinZAnJHouJChenZ.Exendin-4 enhances proliferation of senescent osteoblasts through activation of the IGF-1/IGF-1R signaling pathway. Biochem Biophys Res Commun2019;
516:300–6
7.
ZhangLLiPTangZDouQFengB.Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE(-/-) mice. Ann Transl Med2019;
7:369
8.
ErikssonRBrobergBVIshoyPLBakNAndersenUBJorgensenNRKnopFKEbdrupBH.Bone status in obese, non-diabetic, antipsychotic-treated patients, and effects of the Glucagon-Like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density. Front Psychiatry2018;
9:781
9.
SchiellerupSPSkov-JeppesenKWindelovJASvaneMSHolstJJHartmannBRosenkildeMM.Gut hormones and their effect on bone metabolism. Potential drug therapies in future osteoporosis treatment. Front Endocrinol (Lausanne)2019;
10:75
10.
GaoLLiSLLiYK.Liraglutide promotes the osteogenic differentiation in MC3T3-E1 cells via regulating the expression of Smad2/3 through PI3K/akt and wnt/beta-Catenin pathways. DNA Cell Biol2018;
37:1031–43
11.
Nuche-BerenguerBLozanoDGutierrez-RojasIMorenoPMarinosoMLEsbritPVillanueva-PenacarrilloML.GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol2011;
209:203–10
12.
LuNSunHYuJWangXLiuDZhaoLSunLZhaoHTaoBLiuJ.Glucagon-like peptide-1 receptor agonist liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS One2015;
10:e0132744
13.
MaXMengJJiaMBiLZhouYWangYHuJHeGLuoX.Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res2013;
28:1641–52
14.
SuBShengHZhangMBuLYangPLiLLiFShengCHanYQuSWangJ.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine2015;
48:107–15
15.
NissenAMarstrandSSkov-JeppesenKBremholmLHornumMAndersenUBHolstJJRosenkildeMMHartmannB.A pilot study showing acute inhibitory effect of GLP-1 on the bone resorption marker CTX in humans. JBMR Plus2019;
3:e10209
16.
NauckMABaranovORitzelRAMeierJJ.Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?Diabetologia2013;
56:1878–83
17.
KnudsenLBKielDTengMBehrensCBhumralkarDKodraJTHolstJJJeppesenCBJohnsonMDde JongJCJorgensenASKercherTKostrowickiJMadsenPOlesenPHPetersenJSPoulsenFSidelmannUGSturisJTruesdaleLMayJLauJ.Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A2007;
104:937–42
18.
CheangJYMoylePM.Glucagon-Like peptide-1 (GLP-1)-based therapeutics: current status and future opportunities beyond type 2 diabetes. Chem Med Chem2018;
13:662–71
19.
SamsonSLGarberAJ.A plethora of GLP-1 agonists: decisions about what to use and when. Curr Diab Rep2016;
16:120
20.
JunLSShowalterADAliNDaiFMaWCoskunTFicorilliJVWheelerMBMichaelMDSloopKW.A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor. PLoS One2014;
9:e93746
21.
HeMGuanNGaoWWLiuQWuXYMaDWZhongDFGeGBLiCChenXYYangLLiaoJYWangMW.A continued Saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities. Acta Pharmacol Sin2012;
33:148–54
22.
CheongYHKimMKSonMHKaangBK.Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently. Biochem Biophys Res Commun2012;
417:558–63
23.
WestGMWillardFSSloopKWShowalterADPascalBDGriffinPR.Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain. PLoS One2014;
9:e105683
24.
IrwinNFlattPRPattersonSGreenBD.Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur J Pharmacol2010;
628:268–73
25.
SloopKWWillardFSBrennerMBFicorilliJValasekKShowalterADFarbTBCaoJXCoxALMichaelMDGutierrez SanfelicianoSMTebbeMJCoghlanMJ.Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes2010;
59:3099–107
26.
KimSJHwangYHMunSKHongSGKimKJKangKYSonYJYeeST.Protective effects of 2,3,5,4′-Tetrahydroxystilbene-2-O-β-d-glucoside on ovariectomy induced osteoporosis mouse model. Int J Mol Sci2018;
19:2554
27.
WangYDaiJZhuYZhongWLuSChenHChaiY.Paeoniflorin regulates osteoclastogenesis and osteoblastogenesis via manipulating NF-kappaB signaling pathway both in vitro and in vivo. Oncotarget2018;
9:7372–88
28.
GaoPZhangHLiuYFanBLiXXiaoXLanPLiMGengLLiuDYuanYLianQLuJGuoZWangZ.Beta-tricalcium phosphate granules improve osteogenesis in vitro and establish innovative osteo-regenerators for bone tissue engineering in vivo. Sci Rep2016;
6:23367
29.
WenBZhaoLZhaoHWangX.Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis. Exp Ther Med2018;
15:5077–83
30.
AghajanianPMohanS.The art of building bone: emerging role of chondrocyte-to-osteoblast transdifferentiation in endochondral ossification. Bone Res2018;
6:19
31.
ZhangLZhangWTianX.The pleiotropic of GLP-1/GLP-1R axis in Central nervous system diseases. Int J Neurosci2021;1–38. doi: 10.1080/00207454.2021.1924707
32.
ZhangHLiuYGuanSQuDWangLWangXLiXZhouSZhouYWangNMengJMaX.An orally active allosteric GLP-1 receptor agonist is neuroprotective in cellular and rodent models of stroke. PLoS One2016;
11:e0148827
33.
Montes CastilloMCMartínez RamírezMJSoriano ArroyoRPrieto GomezISegarra RoblesABGarrido-MartínezMSantiago-FernándezPDelgado RodríguezM.Glucagon-like peptide 1 and glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women. Sci Rep2019;
9:13651
34.
ButeraPC.Estradiol and the control of food intake. Physiol Behav2010;
99:175–80
35.
LutzTA.Amylin may offer (more) help to treat postmenopausal obesity. Endocrinology2011;
152:1–3
36.
GraafCDonnellyDWoottenDLauJSextonPMMillerLJAhnJMLiaoJFletcherMMYangDBrownAJZhouCDengJWangMW.Glucagon-Like peptide-1 and its class B G Protein-Coupled receptors: a long march to therapeutic successes. Pharmacol Rev2016;
68:954–1013
37.
KanoskiSEFortinSMArnoldMGrillHJHayesMR.Peripheral and Central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology2011;
152:3103–12
38.
HoareSR.Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov Today2005;
10:417–27
39.
DiemarSSMøllehaveLTQuardonNLylloffLThuesenBHLinnebergAJørgensenNR.Effects of age and sex on osteocalcin and bone-specific alkaline phosphatase-reference intervals and confounders for two bone formation markers. Arch Osteoporos2020;
15:26
40.
GarneroPSornay-RenduEChapuyMCDelmasPD.Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res1996;
11:337–49
41.
RaiszLG.Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest2005;
115:3318–25
42.
LiuZChenRJiangYYangYHeLLuoCDongJRongL.A meta-analysis of serum osteocalcin level in postmenopausal osteoporotic women compared to controls. BMC Musculoskelet Disord2019;
20:532
43.
Nuche-BerenguerBMorenoPPortal-NunezSDapiaSEsbritPVillanueva-PenacarrilloML.Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept2010;
159:61–6
ZhaoCLiangJYangYYuMQuX.The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms. Front Endocrinol (Lausanne)2017;
8:98
46.
KimJYLeeSKJoKJSongDYLimDMParkKYBonewaldLFKimBJ.Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci2013;
92:533–40
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
